Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High Risk Prostate Cancer Prevention Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Kansas
ClinicalTrials.gov Identifier:
NCT01174953
First received: July 26, 2010
Last updated: December 30, 2013
Last verified: December 2013

July 26, 2010
December 30, 2013
July 2010
March 2013   (final data collection date for primary outcome measure)
Biomarkers will be identified to help predict future prostate cancer risks and patients likely to benefit from preventive strategies [ Time Frame: 2 years from completion of enrollment ] [ Designated as safety issue: Yes ]
identify biomarkers to help predict future prostate cancer risks and patients likely to benefit from preventive strategies [ Time Frame: 2 years from completion of enrollment ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01174953 on ClinicalTrials.gov Archive Site
provide a platform ongoing evaluation of novel preventive agents [ Time Frame: approximately 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
High Risk Prostate Cancer Prevention Study
High Risk Prostate Cancer Prevention Study

The purpose of this study is to study the molecular effects of the chemopreventative agent, finasteride, in combination with dietary soy supplementation in patients at high risk for the development of prostate cancer. Also, the investigators intend to create a large database with health information from men who are at high risk of developing prostate cancer, along with serum and tissue samples from those patients who are willing to provide tissue and serum samples.

Over 180,000 new cases of prostate cancer are diagnosed in the United States each year, making prostate cancer the most frequently diagnosed cancer in men. With an estimated 28,660 deaths occurring in 2008, prostate cancer is the second leading cause of cancer death in men. In Kansas, prostate cancer is also the most frequent cancer among men and ranked third (253 deaths in 2006) behind lung cancer (884 deaths in 2006) and colorectal cancer (273 deaths in 2006) in cancer related mortality. Despite the significant morbidity and mortality related to this disease, screening and treatment approaches remain controversial and there is significant morbidity related to the treatment of early stage disease. Preventative strategies and strategies which identify patients at highest risk are needed desperately.

The goal of this proposal is to study the molecular effects of the chemopreventative agent, finasteride in combination with dietary soy supplementation in patients at high risk for the development prostate cancer.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Prostate Cancer
Drug: finasteride

Finasteride 5 mg once daily

Soy 4 capsules twice daily (160 mg total)

Other Names:
  • Proscar
  • Propecia
  • isolavone
Finasteride plus soy
Finasteride and soy
Intervention: Drug: finasteride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Based on the PSA, DRE and Family history of prostate cancer patients will be risk stratified using Prostate Cancer Risk Calculator. Must have at least 25% chance of prostate cancer development as assessed by the prostate cancer risk calculator.
  2. During time of study period, patients must agree not to take any new vitamin supplementation, soy or herbal supplement.
  3. Must not be receiving concurrent chemotherapy, radiation or hormonal therapy.
  4. No history of prior allergy and intolerability to soy-based products.
  5. Must not have been taking any soy supplementation, soy isoflavones or finasteride within 90 days prior to study enrollment.
  6. Must be able to safely be on study supplements for period of at least four months.
  7. All patients must have been informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
  8. All patients must be willing to undergo prestudy and follow-up assessment, including prostate biopsies.

Exclusion Criteria:

  1. Patients diagnosed with prostate cancer on initial biopsy
  2. Patients with any active malignancy
  3. Receiving any concurrent chemotherapy, hormonal therapy or radiation
  4. Patient not compliant with treatment for at least 4 months
  5. Patients with history of deep vein thrombosis, myocardial infarction, coronary artery disease,and cerebrovascular accident in the last 6 months will also be excluded.
  6. Patients on active anticoagulation will be excluded.
  7. Patients with liver function tests more than 2 levels of upper limit of normal
  8. Patients who develop more than grade 2 toxicity will also be removed from the study
Male
55 Years to 95 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01174953
12052
Yes
University of Kansas
University of Kansas
Not Provided
Principal Investigator: Peter J Van Veldhuizen, MD University of Kansas
University of Kansas
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP